Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1557229 | 0.89 | GPR119 (0.60) | GPR119 | |
| SCHEMBL1556639 | 0.86 | GPR119 (0.48) | GPR119USP2MAPK1ALDH1A1HPGD | |
| SCHEMBL1557150 | 0.85 | GPR119 (0.47) | GPR119HPGDKMT2AMEN1RXRA | |
| SCHEMBL11307513 | 0.85 | GPR119 (0.43) | GPR119RXRAGRIN1GRIN2B | |
| Hydrochloric Acid SCHEMBL1557787 | 0.84 | GPR119 (0.42) | GPR119RXRAGRIN1GRIN2B | |
| SCHEMBL1578058 | 0.84 | GPR119 (0.47) | GPR119USP2MAPK1ALDH1A1HPGD | |
| SCHEMBL1556593 | 0.84 | GPR119 (0.43) | GPR119USP2MAPK1ALDH1A1HPGD | |
| SCHEMBL1557532 | 0.83 | GPR119 (0.49) | GPR119RXRAGRIN1GRIN2B | |
| SCHEMBL14142053 | 0.82 | GPR119 (0.45) | GPR119USP2MAPK1ALDH1A1HPGD | |
| SCHEMBL1577809 | 0.80 | GPR119 (0.43) | GPR119USP2MAPK1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184572-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | METABOLEX, INC. | 2012-07-19 | — | — | US | disclosed |
| US-20110294836-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| EP-2303859-A2 | ARYL GPR119 AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010008739-A2 | ARYL GPR119 AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184572-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | GPR119, GPR27, GPR65 | GPR119 1/4885USP2 1701/4885MAPK1 2390/4885 |
| US-20110294836-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | GPR119, GPR27, GPR65 | GPR119 1/4885USP2 1701/4885MAPK1 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.